The settlement removes litigation uncertainty and future royalty payments, but the $17M cash outflow and termination of the license agreement warrant monitoring of Collegium's cash position and any impact on Nucynta product margins. Watch for updated guidance on Nucynta revenue and operating expenses in the next quarterly filing.
Price Chart
Executive Summary
Collegium Pharmaceutical settled its patent litigation with Grünenthal by paying $17 million to terminate the Grünenthal License and Consent Agreement, eliminating future royalty obligations and acquiring certain Nucynta-related patents. The settlement resolves the February 2026 patent infringement lawsuit over the authorized generic for Nucynta ER and removes a key overhang, but the $17 million cash payment and loss of the license structure represent a material financial event.
Key Facts
- Collegium and Grünenthal entered into a Settlement Agreement on October 15, 2026, resolving all disputes including the Nucynta Litigation.
- The Grünenthal License and the Consent Agreement (with respect to the Territory) were mutually terminated effective October 15, 2026.
- Collegium paid Grünenthal $17,000,000 as part of the settlement.
- All royalty obligations under the Grünenthal License have been fully discharged; no further royalties will be due.
- Grünenthal assigned certain patents related to the Nucynta Products to Collegium and filed a motion to dismiss the Nucynta Litigation.
- The Consent Agreement continues in full force except for the termination with respect to the Territory.
Financial Impact
One-time cash payment of $17,000,000 to Grünenthal; elimination of future royalty obligations under the Grünenthal License (amount of royalties not disclosed).
Risk Factors
- The $17 million payment reduces cash reserves; no disclosure of remaining cash runway.
- Termination of the license may affect Collegium's ability to manufacture or distribute Nucynta products if the assigned patents are insufficient.
- The settlement resolves current litigation but does not preclude future disputes over the Nucynta product line.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-116876 |
| Document: 0001104659-26-116876-index-headers.html | 0001104659-26-116876 |
| Document: 0001104659-26-116876-index.html | 0001104659-26-116876 |
| Document: 0001104659-26-116876.txt | 0001104659-26-116876 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $23.50 $22.96 | ▼ −2.30% | ▼ −1.78% | $23.21 (−1.23%) |
Oct 19, 2026 7d ago | 8-K | $23.23 $22.92 | ▼ −1.36% | ▼ −1.88% | $23.21 (−0.09%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.09 $22.05 | ▼ −0.18% | ▼ −0.12% | $23.21 (+5.07%) |
Aug 19, 2026 9w ago | Court Ruling | $27.54 $27.11 | ▼ −1.56% | ▼ −1.97% | $23.21 (−15.72%) |
Aug 13, 2026 10w ago | 8-K | $28.15 $28.23 | ▲ +0.28% | ▲ +0.48% | $23.21 (−17.55%) |
Aug 6, 2026 11w ago | 8-K | $29.11 $29.47 | ▲ +1.24% | ▲ +0.63% | $23.21 (−20.27%) |
May 15, 2026 23w ago | Insider Cluster | $33.65 $33.62 | ▼ −0.09% | ▲ +0.56% | $23.21 (−31.03%) |
May 12, 2026 23w ago | Press Release | $35.69 $34.87 | ▼ −2.30% | ▼ −2.87% | $23.21 (−34.97%) |
May 11, 2026 24w ago | 144 | $35.81 $35.69 | ▼ −0.34% | ▼ −0.20% | $23.21 (−35.19%) |
Apr 23, 2026 26w ago | Press Release | $32.28 $32.50 | ▲ +0.68% | ▼ −0.10% | $23.21 (−28.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers